NEW YORK, April 23, 2015 /PRNewswire/ — Tisch MS Research Center of New York (Tisch MSRCNY) today announced encouraging preliminary results from its FDA-approved Phase I trial using autologous neural stem cells in the treatment of multiple sclerosis (MS). MS is a chronic autoimmune disease of the central nervous system where the myelin sheath is attacked […]

LAUSANNE, Switzerland, April 23, 2015 /PRNewswire/ — Debiopharm International SA (Debiopharm), part of Debiopharm Group™, a Swiss-based global biopharmaceutical company, today announced the start of a clinical phase II study to evaluate Debio 1450 for the treatment of Acute Bacterial Skin and Skin Structure Infections (ABSSSI) due to Staphylococci, including all resistant Staphylococcus strains, tested so far. This study […]

CORK, Ireland, April 23, 2015 /PRNewswire/ — Janssen Sciences Ireland UC, one of the Janssen Pharmaceutical Companies of Johnson & Johnson (Janssen), today announced results for its hepatitis C treatment simeprevir at The International Liver Congress™ 2015 of the European Association for the Study of the Liver (EASL) in Vienna. Late-breaking results from the Phase 3 […]

A woman holds her stomach at the last stages of her pregnancy in Bordeaux April 28, 2010. Reuters/Regis Duvignau (Reuters Health) – Children born to women who suffered severe nausea and vomiting during pregnancy are more likely to be diagnosed with neurological developmental disorders, according to a small U.S. study. Compared to children of women […]

  <span class=”articleLocatio n”>(Reuters) – Boehringer Ingelheim Pharmaceuticals Inc said its emergency blood clotting agent was granted a priority review status by the U.S. Food and Drug Administration, accelerating the regulatory process by four months. The drug, idarucizumab is specifically being tested to reverse the blood thinning effects of Pradaxa, the privately held company said […]

NEWARK, CA–(Marketwired – April 23, 2015) – CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company developing therapies to treat metabolic diseases with high unmet medical need, today announced the initiation of a Phase 2 study of MBX-8025 in patients with homozygous familial hypercholesterolemia (HoFH). MBX-8025 is an orally administered potent and selective peroxisome proliferator-activated receptor […]

PHOENIX, AZ–(Marketwired – Apr 23, 2015) – Insys Therapeutics, Inc. (NASDAQ: INSY) (“Insys” or “the Company”) today announced that it has commenced dosing of pediatric epilepsy patients in a Phase 1/2 safety and pharmacokinetic (PK) study in pediatric subjects with treatment-resistant seizures. The clinical trial will evaluate multiple ascending doses of Insys’ pharmaceutical cannabidiol (CBD) […]

AURORA, ON–(Marketwired – Apr 22, 2015) –  Helix BioPharma Corp. (TSX: HBP) (FRANKFURT: HBP) NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRES OR DISSEMINATION IN THE UNITED STATES First Patient Dosed and Three Clinical Sites Initiated Helix BioPharma Corp. (TSX: HBP) (FRANKFURT: HBP), a biopharmaceutical company developing innovative drug candidates for the prevention and treatment of […]

WHIPPANY, N.J., April 22, 2015 /PRNewswire/ — Bayer is pleased to announce today that the U.S. Food and Drug Administration (FDA) has accepted the filing for Bayer’s supplemental Biologics License Application (sBLA) for BETACONNECT TM (proposed name), another delivery option for BETASERON® (interferon beta-1b), a treatment for relapsing-remitting multiple sclerosis. “This filing underscores Bayer’s continued, longstanding […]

(Reuters) – Swiss drugmaker Roche has “renewed confidence” that drugs targeting potentially brain-destroying plaque can fight Alzheimer’s disease, following promising results with a product from a rival. Pharmaceuticals head Daniel O’Day said on Wednesday Roche would look again at prospects for two of its experimental Alzheimer’s drugs, both of which suffered setbacks in 2014, in […]